Case Study: Immatics achieves streamlined TCR R&D workflows and centralized data access with Genedata Biologics

Immatics Builds on Genedata Biologics for Cell Therapy Innovation

Immatics, a clinical‑stage biopharmaceutical company developing T cell receptor (TCR)‑based immunotherapies, needed a purpose‑built enterprise software solution to increase the efficiency and traceability of its complex TCR engineering workflows for cell and gene therapy R&D. After a market assessment, Immatics selected Genedata and adopted the Genedata Biologics platform to support its proprietary XPRESIDENT® and XCEPTOR® technologies and to centralize TCR‑related data across teams (Genedata customer since 2019).

Genedata configured Genedata Biologics to Immatics‑specific CGT workflows and deployed it rapidly without extensive customization, providing integrated dashboards, hit‑selection tools, and end‑to‑end tracking of molecules, cell lines, assays and decisions. As a result, Immatics achieved streamlined workflows, central real‑time access to all TCR R&D data, improved cross‑team collaboration and more transparent decision‑making, with reduced manual errors, measurable efficiency gains and ongoing cost savings that outweighed the initial investment.

Immatics

Dominik Maurer

Vice President of Immunology